BriaCell to Present Bria-OTS+™
BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting
PHILADELPHIA and VANCOUVER, British Columbia, -- BriaCell Therapeutics Corp., a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the Company will be presenting preclinical Bria-OTS+ data at a poster presentation at the Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting, held November 7-9, 2025, in National Harbor, MD.
Title: Redefining Cancer Vaccines: Bria-OTS+ Integrates Trained Innate Immunity and Adaptive Memory to Overcome Immune Resistance. Abstract Number: 353
Location: Prince George ABC Exhibit Halls Gaylord National Resort and Convention Center. Date: Friday, Nov. 7, 2025
About BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company developing personalized immunotherapies for cancer, focusing on its lead candidate Bria-IMT, a cell-based immunotherapy, currently in a Phase 3 trial for metastatic breast cancer. The company also has the Bria-OTS platform for personalized therapies and a soluble CD80 protein therapeutic.
Focus: Developing novel immunotherapies to transform cancer treatment, with an initial focus on breast cancer. Bria-IMT, a patented, off-the-shelf, cell-based targeted immunotherapy that activates the patient's immune system to kill cancer cells. Bria-IMT is in a Phase 3 clinical trial in combination with Retifanlimab (an anti-PD-1 antibody) for metastatic breast cancer.
